5 results
- To asses the safety and toxicity of peri-ablative sorafenib given in doses of either 200 mg or 400 mg twice daily.- To asses the effect of perioperative sorafenib on the RFA induced mobilization of endothelial progenitor cells and cytokines…
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
To perform a pre-study to assess the feasibility of DE-MRI to assess lesion size, transmurality and completeness of pulmonary vein isolation. The study will be performed to determine if and how DE-MRI can be used in a larger subsequent multicentre…
To evaluate the efficacy and safety of BIBF 1120 in HCC patients without prior systemic treatment as compared to Sorafenib.
The revised aims of the SORCE trial are:1. Does up to three years of treatment with sorafenib increase DFS compared with placebo: a comparison of Arm C vs Arm A2. If the answer to question (i) is yes, does one year of sorafenib (Arm B) increase DFS…